Scoreboard / CRL
Charles River Laboratories CRL
Issue No. 07 pick · August 7, 2026 · Updated September 4, 2026
Setup Snapshot
The Setup in One Card
How CRL moved and the catalyst behind the move, from its Issue No. 07 write-up. It is not on the current Scoreboard, so it carries no Friday Five Score this week.
Issue No. 07
Original Pick
Sector Trend
Improvingup 1.0 percent
Covered In
Issue No. 07 · August 7, 2026
Catalyst
Guidance RaiseRaised full year guidance on the best bookings in nearly four years despite falling revenue
Return measured from the Thursday, July 30 close to the Thursday, August 6 close, the week it appeared in Issue No. 07.
Why It Moved
The Story Behind the Move
Catalyst
Raised full year guidance on the best bookings in nearly four years despite falling revenue
Why It Mattered
This was the only raise in the issue that marks a business turning rather than a business accelerating. Shrinking research budgets at drug developers created the hole, and rising bookings are the first evidence the shrinking has stopped.
Risk Note
Revenue is still declining year over year and the company posted a GAAP loss, so the inflection is argued from orders rather than results. Research budgets can be cut again faster than a backlog converts.
Reader Takeaway
A guidance raise from a company with falling revenue is a statement about direction, not about health. Those are worth more when orders back them and less when they do not.
Continue the Research
Put CRL Back in Context
The stock page is one piece of the weekly research. Continue with the original issue, the full public ranking, or the method behind the analysis.
This page is for educational and informational purposes only. It is not financial advice, investment advice, or a recommendation to buy or sell any security.